Authors and Disclosures
Edward V. Loftus Jr1, Brian G. Feagan2, Remo Panaccione3, Jean-Frédéric Colombel4, William J. Sandborn5, Bruce E. Sands4, Silvio Danese6, Geert D'Haens7, David T. Rubin8, Ira Shafran9, Andrejus Parfionovas10, Raquel Rogers10, Richard A. Lirio10 and Séverine Vermeire11
1Rochester, MN, USA
2London, ON, Canada
3Calgary, AB, Canada
4New York, NY, USA
5San Diego, CA, USA
6Milan, Italy
7Amsterdam, The Netherlands
8Chicago, IL, USA
9Winter Park, FL, USA
10Cambridge, MA, USA
11Leuven, Belgium
Correspondence
Edward V. Loftus Jr, Mayo Clinic College of Medicine, Rochester, MN, USA. Email: loftus.edward@mayo.edu
Author contributions
All authors had access to the study data; contributed to manuscript drafting, critical review and revision. All authors approved the final manuscript for submission.
Declaration of personal interests
Edward V. Loftus: Financial support for research: AbbVie, Takeda, Janssen, UCB, Amgen, Pfizer, Genentech, Celgene, Receptos, Gilead, Bristol-Myers Squibb, and Robarts Clinical Trials; Consultancy: AbbVie, Takeda, Janssen, UCB, Amgen, Pfizer, Eli Lilly, Celltrion Healthcare, Allergan, Bristol-Myers Squibb, Gilead, Genentech, Celgene, and Boehringer Ingelheim. Brian G. Feagan: Consultancy: Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, Astra Zeneca, Avaxia Biologics Inc, Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc, GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc, Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, VHsquared Ltd., Warner Chilcott, Wyeth, Zealand, and Zyngenia; Grant/research support: Abbott/AbbVie, Amgen, Astra Zeneca, Bristol-Myers Squibb (BMS), Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, and UCB Pharma; Membership (board of directors): Robarts Clinical Trials Inc. Remo Panaccione: Consultancy: AbbVie, Amgen, Allergan, AstraZeneca, Baxter, BMS, Celgene, Cubist, Eisai, Eli Lilly, Ferring, Genentech, Gilead, Janssen, Merck, Robarts, Salix, Samsung, Schering-Plough, Shire, Centocor, Elan, Glaxo-Smith Kline, UCB, Pfizer, and Takeda; Speaker's Bureau: AbbVie, Abbott, Aptalis, AstraZeneca, Ferring, Janssen, Merck, Prometheus, Shire, Takeda; Research/Educational Support from: AbbVie, Abbott, Ferring, Janssen Pharmaceuticals, and Takeda. Jean-Frédéric Colombel: Consultancy/advisory board membership: AbbVie, Amgen, Boehringer-Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen Pharmaceuticals, Medimmune, Merck & Co., Pfizer, Protagonist, Second Genome, Seres, Takeda, and Theradiag; Speaker: AbbVie, Ferring, Takeda, and Shire; Research support: AbbVie, Genentech, and Takeda; Stock options: Intestinal Biotech Development, and Genfit. William J. Sandborn: Research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, AbbVie, Janssen, Takeda, Lilly, Celgene/Receptos, Pfizer, Prometheus Laboratories (now Prometheus Biosciences); consulting fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals; and stock or stock options from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Progenity, Ritter Pharmaceuticals, Ventyx Biosciences, Vimalan Biosciences. Spouse: Opthotech - consultant, stock options; Progenity - consultant, stock; Oppilan Pharma - employee, stock options; Escalier Biosciences - employee, stock options; Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories) - employee, stock options; Ventyx Biosciences – employee, stock options; Vimalan Biosciences – employee, stock options. Bruce E. Sands: Consultancy: 4D Pharma, AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Capella Bioscience, Celgene, Celltrion Healthcare, Eli Lilly and Company, EnGene, F. Hoffmann-La Roche, Ferring, Gilead Sciences, Ironwood Pharmaceuticals, Janssen, Lyndra, MedImmune, Oppilan Pharma, Otsuka America Pharmaceutical, Palatin Technologies, Pfizer, Progenity, Prometheus Laboratories, Protagonist Therapeutics Rheos Medicines, Seres Therapeutics, Shire, Sienna Biopharmaceuticals, Synergy Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma, TiGenix, UCB, Valeant Pharmaceuticals North America, and Vivelix Pharmaceuticals; Research support: Takeda, Janssen, Theravance Biopharma, and Pfizer. Silvio Danese: Lecture fee(s): AbbVie, Ferring, Hospira, Johnson and Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer Ingelheim; Consultancy: AbbVie, Ferring, Hospira, Johnson and Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer Ingelheim. Geert D'Haens: Financial support for research: AbbVie, Buhlmann Laboratories, Ferring, DrFALK Pharma, Johnson and Johnson, GlaxoSmithKline, Medtronics, Millennium/Takeda, MSD, Photopill, Prometheus laboratories, Robarts Clinical Trials, and Setpoint; Lecture fee(s): AbbVie, Biogen, Ferring, DrFALK Pharma, Johnson and Johnson, Giuliani, Millennium/Takeda, MSD, Norgine, Otsuka, Shire, Tillotts, UCB, and Vifor; Consultancy: AbbVie, Ablynx, Actogenix, Amakem, Amgen, AM Pharma, AstraZeneca, Biogen, BMS, Boehringer Ingelheim, Cosmo, Elan, Ferring, Celgene/Receptos, Celltrion, Johnson and Johnson, Engene, Galapagos, Gilead, GlaxoSmithKline, Immunic Therapeutics, Lycera, Medimetrics, Medtronics, Millennium/Takeda, Mitsubishi Pharma, MSD, Mundipharma, Novo Nordisk, Otsuka, Hospira/Pfizer, PDL, Prometheus Laboratories, Protagonist, Salix, Samsung Bioepis, Sandoz, Setpoint, Shire, TEVA, Tigenix, Tillotts, Topivert, UCB, Versant, and Vifor; Directorship(s): Robarts Clinical Trials. David T. Rubin: Consultancy: AbbVie, Abgenomics, Allergan Inc, Amgen, Celgene Corporation, Forward Pharma, Genentech/Roche, Janssen Pharmaceuticals, Merck & Co Inc, Miraca Life Sciences, Mitsubishi Tanabe Pharma Development America Inc, Napo Pharmaceuticals, Pfizer, Salix Pharmaceuticals, Samsung Bioepis, Sandoz Pharmaceuticals, Shire, Takeda, and Target PharmaSolutions Inc; Grant support: AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, Takeda, and UCB Pharma. Ira Shafran: Lecture fee(s): Takeda; Grant support: Takeda. Andrejus Parfionovas: Employee of Takeda. Raquel Rogers: Employee of Takeda. Richard A. Lirio: Employee of Takeda. Séverine Vermeire: Financial support for research: MSD, AbbVie, Takeda, Pfizer, and Johnson & Johnson; Lecture fee(s): MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Tillotts Pharma and Genentech/Roche; Consultancy: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Gilead, Galapagos, Robarts Clinical Trials, Amgen, GlaxoSmithKline, Shire, Arena and ProDigest.